drugset / Trial / NCT01014325

Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy

NCT01014325

Phase 3 Unknown 130 enrolled Roxall
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.

Timeline

Start
2016-09
Primary completion
2017-09
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Allergen extract Unknown Other

Indications